U.S. stock market midday update: Akso Health down 7.80%, active capital flow triggers market volatility attention

U.S. Stock Market Midday Update Akso Health fell 7.80%. There have been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news Stocks with High Trading Volume in the Industry McKesson, down 0.13%, with a trading volume of $70.25 million, has seen increased trading volume and no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Cardinal Health, down 0.01%, with a trading volume of $67.04 million, has seen increased trading volume and no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Cencora, up 0.10%, with a trading volume of $64.21 million, has seen increased trading volume and no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Market Capitalization in the Industry Henry Schein fell 0.22%. Based on recent key news: On December 24, Henry Schein announced that its CEO search process is nearing completion, with a new CEO expected to be appointed in mid-January 2026. Current CEO Stanley Bergman will continue to serve as CEO and Chairman until the new appointment is made. This news may lead to market uncertainty regarding the company's future leadership, thereby affecting the stock price. On December 24, Elizabeth Anderson, an analyst at Evercore ISI, maintained a buy rating on Henry Schein with a target price of $90. The analyst's rating and target price may impact investor confidence, although the market reaction has been minimal. On December 24, the analyst consensus for Henry Schein is moderate buy, with a consensus target price of $76.78. The analyst consensus may influence market expectations but has not significantly driven the stock price. The healthcare industry is currently facing risks related to leadership changes